Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) will hold a conference call on August 4, 2022, at 4:30 p.m. Eastern Time to discuss its second quarter 2022 financial results and provide a business overview. The call will be accessible via telephone registration through an online form, and a live audio webcast will also be available on Ardelyx's website. Ardelyx focuses on developing innovative medicines, including its approved product IBSRELA® and the pipeline candidates XPHOZAH® and RDX013, targeting significant medical needs.

Positive

• First approved product, IBSRELA®, available in the U.S.
• XPHOZAH® has completed three successful Phase 3 trials.

Negative

• None.

— Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass., July 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time to review second quarter 2022 financial results and provide a business overview.

To participate in the conference call via telephone, please register using this online form. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-report-second-quarter-2022-financial-results-on-august-4-2022-301595061.html

SOURCE Ardelyx

FAQ

When will Ardelyx report its second quarter 2022 financial results?

Ardelyx will report its second quarter 2022 financial results on August 4, 2022.

What is the purpose of Ardelyx's conference call on August 4, 2022?

The conference call will review second quarter 2022 financial results and provide a business overview.

How can I access the Ardelyx conference call?

You can access the Ardelyx conference call by registering through their online form, and it will also be available as a live audio webcast on their website.

What innovative products is Ardelyx developing?

Ardelyx is developing XPHOZAH® for controlling serum phosphorus and RDX013 for treating elevated serum potassium.